



Flavivirus Immunotherapy

Guest Editor:

Prof. Dr. Juan Carlos Saiz

Department of Biotechnology,
Instituto Nacional de
Investigación y Tecnología
Agraria y Alimentaria (INIA),
Madrid, Spain

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editor

As the Guest Editor of the Vaccines Special Issue “Flavivirus Immunotherapy”, I would like to invite you to contribute with an original report, original observation, commentary, or review to it.

As you are perfectly aware, flaviviruses (Flaviviridae family) are arthropod-borne viruses, whose genomes are composed of a single RNA molecule of positive polarity. Vaccines are only available for a few flaviviruses and there is no specific therapy on the market for any of them. Thereby, to achieve a more comprehensive understanding of the current trends in flavivirus immunoprophylaxis, this Special Issue of Vaccines is dedicated to recent scientific and technical progress made in this field. Based on your extensive experience and your recent publications, it would be our honor to publish your work to support the global scientific community. We sincerely hope that you accept our invitation. If you can contribute, please let us know at your earliest convenience, and we will provide you with additional details.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com